We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bitter Melon Extract Inhibits Breast Cancer Cell Growth

By LabMedica International staff writers
Posted on 15 Apr 2010
Bitter melon (Momordica charantia) extract, a common dietary supplement, has been show to exert a significant effect against breast cancer cell growth and may ultimately become a chemopreventive agent against this form of cancer.

"Our findings suggest that bitter melon extract modulates several signal transduction pathways, which induces breast cancer cell death,” said lead researcher Ratna B. More...
Ray, Ph.D., a professor in the department of pathology at Saint Louis University (MO, USA). "This extract can be utilized as a dietary supplement for the prevention of breast cancer.”

Results of this study were published in February 15, 2010, issue of Cancer Research, a journal of the American Association for Cancer Research. Previous research has shown bitter melon, to have hypoglycemic and hypolipidemic effects, according to Dr. Ray. Because of these effects, the extract is typically used in folk medicine as a remedy for diabetes, in regions such as India, China, and Central America, according to the researchers.

Using human breast cancer cells and primary human mammary epithelial cells in vitro, Dr. Ray and colleagues found the mechanism of bitter melon extract significantly decreased proliferation in cell growth and division, and induced death in breast cancer cells. These early results offer an encouraging path for research into breast cancer.

"Breast cancer is a major killer among women around the world, and in that perspective, results from this study are quite significant,” said Rajesh Agarwal, Ph.D., professor in the department of pharmaceutical Sciences at the University of Colorado, Denver School of Pharmacy (USA). "This study may provide us with one more agent as an extract that could be used against breast cancer if additional studies hold true.”

According to Dr. Agarwal, the Cancer Research associate editor for this study, the simple study design, clear-cut results, and the overall importance of these findings in breast cancer prevention makes this research different from earlier research. However, he stressed, "This study is only a step towards establishing the cancer preventive efficacy of bitter melon against breast cancer.” Additional research is needed to understand better the molecular targets of bitter melon extract in cancer cells, as well as for establishing its in vivo efficacy. Dr. Agarwal gave a note of caution, stating that while these results do provide hope as an anticancer agent, it is important to establish the validity of these results in animal models before adding them to one's diet to inhibit breast-cancer cell growth.

Dr. Ray and colleagues are currently conducting follow-up studies using a number of cancer cell lines to examine the antiproliferative effect of the extract. They are also planning a preclinical trial to assess its chemopreventive efficacy by oral administration.

Bitter melon extract is cultivated in Asia, Africa, and South America. Extract of this vegetable is being popularized as a dietary supplement in Western Countries, since it is known to contain additional glycosides such as mormordin, vitamin C, carotenoids, flavanoids, and polyphenols.

Related Links:
Saint Louis University
University of Colorado, Denver School of Pharmacy


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.